Injectable GHK-Cu: the gap between topical evidence and the needle
Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board
- No human trial has tested injected GHK-Cu on its own. The human evidence people cite is from skin products, and even that is thin.
- GHK-Cu is about 16% copper by weight. A 50 mg vial contains about 7.9 mg of copper, delivered without passing the gut, one of the body's copper controls.
- Animal studies of injected GHK-Cu are mostly positive, for wound healing and tissue repair, and one ligament effect faded within weeks. Animals are not people.
- FDA says compounded injectable GHK-Cu may cause immune reactions and that human data are limited. Its compounding committee is due to review GHK-Cu by the end of February 2027.
What GHK-Cu is
GHK is a three-amino-acid peptide, glycine-histidine-lysine, found naturally in plasma, saliva and urine, with levels that fall with age 1: a 2020 review from the University of Washington gives an average of about 200 ng/mL in serum at age 20 and about 80 ng/mL by 60 (review) 2. It binds copper tightly, and GHK-Cu is that complex. In laboratory experiments it competes with albumin for copper and forms complexes with albumin itself (laboratory evidence) 3 4. Our encyclopedia lists its formula as C14H23CuN6O4, with a molecular weight of 402.92 5.
Reviews by Loren Pickart and collaborators present a long list of actions they describe as health-positive, from collagen and elastin production to blood-vessel growth and tissue repair, and state that GHK can up- and downregulate at least 4,000 human genes (reviews) 1 6.
The topical evidence, and why it does not transfer
GHK-Cu earned its reputation in skin care, but even there the clinical evidence is surprisingly thin. A 2025 review of cosmetic peptides concluded that cell studies support GHK as an anti-wrinkle ingredient, but found a surprising absence of clinical studies of GHK-Cu or palmitoyl-GHK and limited published data on their skin penetration and effectiveness (review) 7. A second 2025 review noted that GHK-Cu is fairly water-loving and crosses the skin's oily outer layer poorly (review) 8. The one small randomised trial on our entry, after laser skin treatment, in which 13 patients completed the study, found no faster fading of redness and no objective difference in wrinkles or skin quality with GHK-Cu, although patients using it reported higher satisfaction on a questionnaire (randomised trial, small) 9.
Whatever the cream data show, they do not tell us about injection. The reviews above describe GHK-Cu crossing the skin's outer layer poorly 7 8, while an injection places the whole amount in tissue. A PubMed search on October 27, 2026 (GHK-Cu, copper tripeptide or glycyl-histidyl-lysine, with injection, subcutaneous or intravenous, limited to clinical trials or human studies) returned three records and no trial of injected GHK-Cu on its own 10. The nearest is an open study, with no control group, in which 1,000 people received scalp injections of a hair formulation combining several growth factors, thymosin beta-4 and copper tripeptide-1 every three weeks; it reports less hair shedding but cannot separate GHK-Cu from the other ingredients (uncontrolled human study) 11. Evidence grade for injected GHK-Cu alone in people: none.
What the injection studies in animals show
Injected GHK-Cu has been studied in animals, and the results are mostly positive. In rats, GHK-Cu injected into small implanted chambers under the skin increased collagen, protein and other markers of wound repair in step with the dose (animal evidence) 12. In 72 rats after knee ligament reconstruction, four weekly knee injections reduced laxity at six weeks, and the lower concentration stiffened the graft, but neither difference remained at 12 weeks (animal evidence) 13. In mice with chemically induced lung scarring, GHK-Cu injected into the abdomen reduced inflammation and collagen deposition (animal evidence) 14. In mice exposed to cigarette smoke it reduced muscle loss, and in a small human comparison people with COPD had lower blood GHK than healthy controls (animal evidence plus an observational measurement) 15.
These are reasons to run human trials. They are not human trials. None tells us what amount, if any, is safe or useful in a person, how often it can be given, or what repeated copper exposure does over months.
The copper in every vial
The issue unique to GHK-Cu is the metal. From its formula, copper makes up about 15.8% of GHK-Cu by weight 5, so every milligram of the peptide carries about 158 micrograms of copper. The table shows what that means for common amounts. It describes what a vial contains, not an amount to use.
| Amount of GHK-Cu | Copper it contains | Compared with the adult upper limit for oral copper (10 mg a day) |
|---|---|---|
| 1 mg | 158 micrograms | 1.6% |
| 10 mg | 1.58 mg | 16% |
| 50 mg (a common amount in multi-peptide blend vials) | 7.9 mg | 79% |
The US National Institutes of Health gives the tolerable upper intake level for copper as 10,000 micrograms (10 mg) a day for adults, for copper from food and supplements 16. That limit was set for copper taken by mouth. The body normally controls copper through absorption in the gut, excretion in bile and storage in the liver (review) 17. An injection skips the first of those controls. Chronic copper toxicity damages the liver and other organs, most clearly in Wilson's disease, a genetic disorder of copper handling, and in Indian childhood cirrhosis, which the review links to milk boiled or stored in brass vessels 17.
Medicine already gives copper intravenously, in parenteral nutrition for people who cannot eat, and treats it with care: a 2017 review of copper in adult parenteral nutrition says the correct amount must be provided if both deficiency and toxicity are to be avoided, that needs are lower in people with cholestasis, and that the tests used to judge copper status are unreliable (review) 18. How the copper in injected GHK-Cu is handled, how much stays bound to the peptide and how much joins the body's copper pool over repeated injections, has not been studied in people.
FDA's view and the PCAC review, as of October 27, 2026
GHK-Cu is not approved by FDA for injection. FDA's page on bulk substances that may present safety risks in compounding, current as of April 22, 2026, lists GHK-Cu for injectable routes among the substances whose nominations were withdrawn, and says compounded injectable products may pose a risk of immune reactions because of the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety 19. Its 503A category list (Updated May 14, 2026) says GHK-Cu "was removed from category 1 on April 22, 2026, because the nominations for GHK-Cu were withdrawn by the nominators", and that GHK-Cu, except for injectable routes, will be added back to Category 1 because one nominator clarified on May 5, 2026 that it had meant to withdraw only its injectable nomination 20. FDA's Pharmacy Compounding Advisory Committee is due to discuss GHK-Cu, with four other substances, at a meeting before the end of February 2027; FDA's meeting page, current as of April 15, 2026, says the time and location will be scheduled 21. Our guide to the second PCAC five covers that meeting.
GHK-Cu is widely used as an ingredient in topical cosmetic products 5. For athletes, GHK-Cu is not named on WADA's list; our encyclopedia records it under S0, the class for substances with no approval for human therapeutic use, as an inference rather than a listing 5.
GHK-Cu in blend vials
Multi-peptide vials pair GHK-Cu with BPC-157 and TB-500, and sometimes KPV; in the blend presets our calculators use, it is the largest component, 50 mg of a 70 mg or 80 mg vial 5. In those blends the copper load comes along with every draw, and the other peptides' own evidence gaps are added to it. Our pages on the three-peptide blend and the four-peptide blend do the arithmetic, and our KLOW vs GLOW vs Wolverine guide explains the names.
Questions to ask before injecting GHK-Cu
- Has injected GHK-Cu been tested in people? (Our PubMed search on October 27, 2026 found no trial of it on its own.)
- How much copper does the product contain, and how does that add to my copper from food and supplements?
- Do I have liver disease, a problem with bile flow, or a family history of Wilson's disease?
- What exactly is in the vial, and does a certificate of analysis from an identifiable laboratory confirm the peptide, its copper content and its purity?
- Would a topical product, which at least has a cosmetic safety record, serve the same purpose?
What would change the picture
The gap could be closed. A useful first human study would give injected GHK-Cu, at defined amounts, to a small group of volunteers under monitoring, and measure what happens to the peptide and its copper: how long each stays in the blood, how much copper ends up bound to albumin and how much in the liver's stores, and whether markers of liver function or copper status change over repeated doses. Only then would efficacy trials make sense, with a defined condition, a control group and an outcome a patient would notice, such as how fast a wound closes. Until then, neither the benefit nor the copper question has an answer, and FDA's committee will be weighing a file with limited human data 19.
The bottom line
GHK-Cu is a real molecule with interesting biology and mostly positive animal studies. But the human evidence people quote is from skin products, and even that is thin; the injected version has not been tested on its own in a human trial. Every vial carries a meaningful amount of copper delivered past the gut, and FDA flags immune-reaction risks and limited human data. Until trials exist, injecting GHK-Cu is an experiment with no data on the outcome.
Frequently asked questions
Is GHK-Cu injection safe?
Unknown. No human trial has tested injected GHK-Cu on its own. FDA says compounded injectable GHK-Cu may pose immune-reaction risks and that human safety data are limited.
How much copper is in GHK-Cu?
About 15.8% by weight, so 1 mg of GHK-Cu contains about 158 micrograms of copper and 50 mg about 7.9 mg. The US upper limit for copper from food and supplements is 10 mg a day for adults.
Does topical GHK-Cu evidence apply to injections?
No. Reviews describe GHK-Cu crossing the skin's outer layer poorly; an injection delivers the full amount into tissue. A 2025 review also found surprisingly few clinical studies even of topical GHK-Cu.
What are the benefits of GHK-Cu injections?
In animals, injected GHK-Cu improved wound repair and lung scarring, and ligament graft healing for a few weeks. None of these has been tested in people.
What has FDA said about injectable GHK-Cu?
FDA's page on bulk substances that may present safety risks in compounding says compounded injectable GHK-Cu may pose a risk of immune reactions (immunogenicity) because of the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety. It lists injectable GHK-Cu among the withdrawn Category 2 nominations.
Is GHK-Cu legal?
It is widely used in topical cosmetics but is not FDA-approved for injection. FDA lists injectable GHK-Cu among withdrawn Category 2 nominations, put non-injectable GHK-Cu back in Category 1 in its May 14, 2026 list, and its compounding committee is due to review GHK-Cu by the end of February 2027. WADA does not name it; we record it under S0 by inference.
Related on Grey Peptides
Sources
- Pickart, L., et al. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int, 2015, 648108. PMID: 26236730
- Dou, Y., et al. (2020). The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther, 2(1), 58-61. PMID: 35083444
- Lau, S. J., et al. (1981). The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J, 199(3), 649-56. PMID: 7340824
- Bossak-Ahmad, K., et al. (2021). Ternary Cu(2+) Complexes of Human Serum Albumin and Glycyl-l-histidyl-l-lysine. Inorg Chem, 60(22), 16927-16931. PMID: 34730942
- Grey Peptides encyclopedia entry for GHK-Cu: molecular formula C14H23CuN6O4 and weight 402.92, FDA status (not approved for injection), WADA status (S0, inferred); blend compositions from the Grey Peptides blend presets (50 mg GHK-Cu in the 70 mg and 80 mg presets); cosmetic use. Read October 27, 2026.
- Pickart, L., et al. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci, 19(7). PMID: 29986520
- Mortazavi, S. M., et al. (2025). Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts, 15, 30071. PMID: 39963574
- Ogórek, K., et al. (2025). Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? Molecules, 30(1). PMID: 39795193
- Miller, T. R., et al. (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 8(4), 252-9. PMID: 16847171
- Grey Peptides search of PubMed, October 27, 2026: (GHK-Cu OR copper tripeptide OR GHK copper OR glycyl-histidyl-lysine) AND (injection OR injected OR subcutaneous OR intravenous) AND (clinical trial[pt] OR humans[MeSH]): 3 records (a biomaterials study, a narrative review and Kapoor 2018), no trial of injected GHK-Cu on its own.
- Kapoor, R., et al. (2018). Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther, 20(6), 369-379. PMID: 29482481
- Maquart, F. X., et al. (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest, 92(5), 2368-76. PMID: 8227353
- Fu, S. C., et al. (2015). Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res, 33(7), 1024-33. PMID: 25731775
- Ma, W. H., et al. (2020). Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sci, 241, 117139. PMID: 31809714
- Deng, M., et al. (2023). Glycyl-l-histidyl-l-lysine-Cu(2+) rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway. J Cachexia Sarcopenia Muscle, 14(3), 1365-1380. PMID: 36905132
- National Institutes of Health, Office of Dietary Supplements. Copper: Fact Sheet for Health Professionals (Tolerable Upper Intake Level for adults 19 and older, 10,000 mcg a day, for copper from food and supplements; biliary excretion and intestinal absorption keep copper in balance). Read October 27, 2026. NIH ODS
- Pankit, A. N., et al. (2002). Copper metabolic defects and liver disease: environmental aspects. J Gastroenterol Hepatol, 17 Suppl 3, S403-7. PMID: 12472971
- Livingstone, C. (2017). Review of Copper Provision in the Parenteral Nutrition of Adults. Nutr Clin Pract, 32(2), 153-165. PMID: 29927526
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (GHK-Cu, for injectable routes of administration, listed under 'Bulk drug substances nominated but withdrawn'). Content current as of April 22, 2026; read October 27, 2026. FDA
- FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated May 14, 2026): GHK-Cu removed from Category 1 on April 22, 2026 because its nominations were withdrawn; GHK-Cu (except for injectable routes of administration) added back to Category 1 after a nominator clarified on May 5, 2026 that it meant to withdraw only the injectable nomination. Read October 27, 2026. FDA
- FDA. Meeting of the Pharmacy Compounding Advisory Committee (February 2027): agenda including GHK-Cu; time and location 'will be scheduled in the coming months'. Content current as of April 15, 2026; read October 27, 2026. FDA
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead